Anti-obesity product safe in mid-stage study
Key points
- Amylin Pharmaceuticals Inc said on Thursday a mid-stage study of its combination obesity product involving versions of hormones linked to appetite and metabolism yielded positive results.
- The Phase 2, 28-week study randomized 608 overweight or obese patients to either placebo or various doses of the product, which contains the compounds pramlintide and metreleptin.
- Patients with a body mass index of less than 35 treated with the highest dose experienced significantly more weight loss - 11 percent on average compared with 1.8 percent for those on placebo.
- The combination therapy had no suggestion of side effects involving the heart or brain - issues that have doomed other potential obesity treatments.
Amylin Pharmaceuticals Inc said on Thursday a mid-stage study of its combination obesity product involving versions of hormones linked to appetite and metabolism yielded positive results.
The Phase 2, 28-week study randomized 608 overweight or obese patients to either placebo or various doses of the product, which contains the compounds pramlintide and metreleptin.
Patients with a body mass index of less than 35 treated with the highest dose experienced significantly more weight loss - 11 percent on average compared with 1.8 percent for those on placebo.
The combination therapy had no suggestion of side effects involving the heart or brain - issues that have doomed other potential obesity treatments.
Amylin said the results confirm previous mid-stage results with the combination product and "provide a solid foundation for the company's ongoing obesity development program."
NEW YORK (Reuters)
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Weight & Nutrition →
NewsAnti-obesity drug may prevent and treat obesity-related liver disease
A new study on the effect of the anti-obesity drug rimonabant on liver function in obese rats found that it reduced markers of liver damage, decreased levels of pro-inflammatory proteins, and improved lipid profiles.…
3 July 2007
NewsScientist create 'anti-obesity' infant formula
Scientists are developing an infant formula designed to be given to babies to prevent them growing up fat, it was revealed today. The controversial research aims to supplement baby milk with a hormone that suppresses…
26 April 2007
NewsBrown seaweed with anti-obesity potential!
Scientists believe they may have found something to combat obesity and it may also help prevent the onset of diabetes. The find, an edible seaweed containing the carotenoid fucoxanthin, when fed to rats enabled them to…
